Glaxosmithkline
GlaxoSmithKline plc (GSK), a leading name in the pharmaceutical preparation manufacturing industry, is headquartered in the United Kingdom. Founded in 2000 through the merger of Glaxo Wellcome and SmithKline Beecham, GSK has established itself as a key player in the global healthcare landscape, with significant operations across Europe, North America, and emerging markets.
GSK focuses on developing innovative medicines, vaccines, and consumer healthcare products, with a commitment to addressing some of the world's most pressing health challenges. Its core offerings include treatments for respiratory diseases, HIV, and vaccines that are recognised for their efficacy and safety. With a strong emphasis on research and development, GSK has achieved notable milestones, including advancements in immunology and oncology, solidifying its position as a trusted leader in the pharmaceutical sector.
+62 vs industry average
Glaxosmithkline’s score of 100 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Glaxosmithkline?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has reduced its overall emissions by 19% since 0
Emissions trajectory 2020 – 2028
Reported emissions
Scope 3 accounts for ••• of total emissions.
Glaxosmithkline's reported carbon emissions
GlaxoSmithKline (GSK), a UK-based pharmaceutical preparation manufacturing company, has set ambitious climate targets, aiming for net-zero greenhouse gas emissions across its full value chain by 2045.
In terms of emissions, GSK reported the following for the latest available years:
- 2025:
- Scope 1 emissions: Approximately 479,000,000 kg CO2e.
- Scope 2 market-based emissions: Approximately 7,000,000 kg CO2e.
- Scope 2 location-based emissions: Approximately 212,000,000 kg CO2e.
- Scope 3 emissions data was not available for this year.
- 2024:
- Total emissions: Approximately 13,905,000,000 kg CO2e.
- Scope 1 emissions: Approximately 521,000,000 kg CO2e.
- Scope 2 market-based emissions: Approximately 44,000,000 kg CO2e.
- Scope 3 emissions: Approximately 8,385,000,000 kg CO2e.
- 2023:
- Total emissions: Approximately 14,563,000,000 kg CO2e.
- Scope 1 emissions: Approximately 580,000,000 kg CO2e.
- Scope 2 market-based emissions: Approximately 64,000,000 kg CO2e.
- Scope 3 emissions: Approximately 8,983,000,000 kg CO2e.
- 2022:
- Total emissions: Approximately 14,886,000,000 kg CO2e.
- Scope 1 emissions: Approximately 626,000,000 kg CO2e.
- Scope 2 market-based emissions: Approximately 88,000,000 kg CO2e.
- Scope 3 emissions: Approximately 8,995,000,000 kg CO2e.
GSK has established several climate reduction targets:
- A commitment to reduce absolute Scope 1 and 2 greenhouse gas (GHG) emissions by 80% by 2030, from a 2020 base year.
- A commitment to reduce absolute Scope 3 GHG emissions across specified categories by 80% by 2030, from a 2020 base year.
- A long-term target to reduce absolute Scope 1 and 2 GHG emissions by 90% by 2045, from a 2020 base year.
- A long-term target to reduce absolute Scope 3 GHG emissions across specified categories by 90% by 2045, from a 2020 base year.
- A commitment to reach net-zero greenhouse gas emissions across its value chain by 2045.
- Previously, GSK committed to reduce absolute Scope 1 and 2 GHG emissions by 34% by 2025 from a 2017 base year, and absolute Scope 3 GHG emissions by 16% by 2030 from a 2017 base year.
In 2021, GSK reported a 15% reduction in its Scope 1 and 2 carbon emissions compared to 2020. GSK has also committed to be Science Based Targets initiative (SBTi) Net Zero Standard by 2045, with at least a 90% absolute reduction in emissions and the remainder addressed through high-quality carbon credits. GSK is a signatory to the Climate Pledge.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Glaxosmithkline’s Climate Goals (2030 & 2050)
5 goals2045
90% reduction in all scopes
by 2045 we will reduce carbon emissions by at least 90%, with the remainder tackled through high-quality offsets.
2030
62% reduction in total GHG
Vs 2019 baseline. Validated by SBTi. Includes full supply chain.
2040
50% reduction in Scope 3 intensity
Across purchased goods and services and logistics.
See all 5 climate goals
Already have an account? Sign in now
Scope 3 top emissions categories
11 of 15 categories disclosedSee all scope 3 categories
Already have an account? Sign in now
Climate initiatives
Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact Climate Champions initiative
RE 100
Climate Action 100
Emissions comparison with industry peers
View similar organisations
Glaxosmithkline
Frequently asked questions
Common questions about Glaxosmithkline’s sustainability data and climate commitments
Data year: 2024
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project